RE: msg from atul

From: "Bachman, William" <bachmanw@globomax.com> Subject: RE: msg from atul Date: Tue, 14 Nov 2000 15:51:39 -0500 Atul: Just a few quick comments off the top of my head: It is possible that either the pharmacokinetics or the residual error structure is different between your phase I and III subjects (or both). This can be tested in the former case by including STUDY as a covariate and testing for inclusion as a covariate on model parameters (and significance) and in the latter case by coding a different residual error model for phase I and phase III data. It can often be helpful to model sparse data with rich data if the sparse data is lacking in information. However, you need to be aware that the populations from which the data arise may not be the same and to account for the differences if possible. I don't foresee a problem looking for covariates in modeling the combined data as long as one of the potential covariates is STUDY. Bill William J. Bachman, Ph.D. Senior Scientist GloboMax LLC 7250 Parkway Drive, Suite 430 Hanover, MD 21076 Telephone: (410) 782-2212 FAX: (410) 712-0737